Y-320 |
| Catalog No.GC13066 |
immunomodulator
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 288250-47-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Y-320 is a new phenylpyrazoleanilide immunomodulator [1].
Immunotherapy refers to treatment of disease by suppressing, inducing or enhancing an immune response.
Y-320 is a new phenylpyrazoleanilide immunomodulator. Y-320 inhibited IL-17 production by CD4 T cells induced by IL-15 with IC50 values of 20-60 nM [1].
In type II collagen-induced arthritis (CIA) mice, oral administration of Y-320 (0.3-3 mg/kg) reduced IL-17 mRNA expression and significantly inhibited the development of joint destruction and arthritis. The combination of Y-320 with anti-murine tumor necrosis factor-α (TNF-α) monoclonal antibody exhibited a synergistic effect. In cynomolgus monkeys, Y-320 (0.3-1 mg/kg) relieved CIA. These results suggested that Y-320 could be a useful candidate for therapy of rheumatoid arthritis (RA) [1].
Reference:
[1]. Ushio H, Ishibuchi S, Oshita K, et al. A new phenylpyrazoleanilide, y-320, inhibits interleukin 17 production and ameliorates collagen-induced arthritis in mice and cynomolgus monkeys. Pharmaceuticals (Basel), 2013, 7(1): 1-17.
Average Rating: 5 (Based on Reviews and 36 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *